Through a combination of metabonomic, transcriptomic, and molecular biology studies, Chi was verified to resensitize IM-resistant CML cells via the PPARγ/mTOR/PKM2 pathway. The gene discussed is PPARG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.